Research Paper Volume 13, Issue 22 pp 24560—24579
Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
Figure 6. EGFR blockage prevents NSCLC cell progression induced by miR-491-5p knockdown. (A) The expression level of EGFR was confirmed by qRT-PCR. n = 4, *P < 0.05 vs. si-miR-NC, #P < 0.05 vs. si-miR-491-5p. (B) CCK-8 assay was performed to detect cell viability in NSCLC cells. n = 4, *P < 0.05 vs. si-miR-NC, #P < 0.05 vs. si-miR-491-5p. (C) The cell cycle was explored by flow cytometry in NSCLC cells after si-miR-491-5p transfection and AZD-9291 treatment. n = 4, *P < 0.05 vs. si-miR-NC, #P < 0.05 vs. si-miR-491-5p. (D) The invasion ability was explored by Transwell. n = 4, *P < 0.05 vs. si-miR-NC, #P < 0.05 vs. si-miR-491-5p.